tiprankstipranks
Advertisement
Advertisement

CRMD Stock Latest News

Citizens healthcare analysts hold an analyst/industry conference call
The FlyCitizens healthcare analysts hold an analyst/industry conference call
2d ago
CRMD
CorMedix price target raised to $14 from $13 at RBC Capital
PremiumThe Fly
CorMedix price target raised to $14 from $13 at RBC Capital
2d ago
CRMD
Buy Rating Reiterated on REZZAYO Trial Strength and Safety Profile; $13 Price Target Maintained
PremiumRatings
Buy Rating Reiterated on REZZAYO Trial Strength and Safety Profile; $13 Price Target Maintained
2d ago
CRMD
CorMedix Reports Positive Phase III REZZAYO Prophylaxis Results
PremiumCompany Announcements
CorMedix Reports Positive Phase III REZZAYO Prophylaxis Results
3d ago
8K
CRMD
CorMedix announces ReSPECT clinical trial met primary endpoint
PremiumThe Fly
CorMedix announces ReSPECT clinical trial met primary endpoint
3d ago
CRMD
3 ‘Strong Buy’ Low P/E Stocks with Over 40% Upside
PremiumMarket News3 ‘Strong Buy’ Low P/E Stocks with Over 40% Upside
10d ago
GEO
CRMD
Cormedix: Undervalued Biotech with Differentiated Lead Asset and Attractive Risk‑Reward Justifying a Buy Rating
Premium
Ratings
Cormedix: Undervalued Biotech with Differentiated Lead Asset and Attractive Risk‑Reward Justifying a Buy Rating
15d ago
CRMD
Cormedix Earnings Call: Peak DEFENCATH, Tough Road Ahead
Premium
Company Announcements
Cormedix Earnings Call: Peak DEFENCATH, Tough Road Ahead
2M ago
CRMD
CorMedix Reaffirms DefenCath 2027 Sales and Outlook
PremiumCompany Announcements
CorMedix Reaffirms DefenCath 2027 Sales and Outlook
2M ago
8K
CRMD
CorMedix affirms FY26 revenue view of $300M-$320M, consensus $308.7M
PremiumThe Fly
CorMedix affirms FY26 revenue view of $300M-$320M, consensus $308.7M
2M ago
CRMD
CorMedix price target lowered to $13 from $15 at Leerink
PremiumThe Fly
CorMedix price target lowered to $13 from $15 at Leerink
2M ago
CRMD
Buy Rating Maintained as Long-Term Rezzayo Upside Remains Underappreciated Despite Near-Term Weakness
PremiumRatings
Buy Rating Maintained as Long-Term Rezzayo Upside Remains Underappreciated Despite Near-Term Weakness
2M ago
CRMD
CorMedix reports Q4 EPS 16c vs 20c last year
PremiumThe FlyCorMedix reports Q4 EPS 16c vs 20c last year
2M ago
CRMD
CRMD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
CRMD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
CRMD
Low P/E Alert! These 3 Undervalued Stocks Are Poised to Surge Over 90%
Premium
Market News
Low P/E Alert! These 3 Undervalued Stocks Are Poised to Surge Over 90%
2M ago
GEO
BTBT
Cormedix: Rezzayo and DefenCath Prophylaxis Upside Underscores Buy Rating and $13 DCF-Based Target
PremiumRatings
Cormedix: Rezzayo and DefenCath Prophylaxis Upside Underscores Buy Rating and $13 DCF-Based Target
3M ago
CRMD
Cormedix: Steady Near-Term Base with High-Impact Label Expansion Catalysts Justifying a Buy Rating
PremiumRatings
Cormedix: Steady Near-Term Base with High-Impact Label Expansion Catalysts Justifying a Buy Rating
3M ago
CRMD
CorMedix board authorizes share repurchase program of up to $75M
PremiumThe Fly
CorMedix board authorizes share repurchase program of up to $75M
3M ago
CRMD
Guardant Health, Jabil, NeoGenomics, Darden, Cormedix Insider Moves
PremiumWeekend Updates
Guardant Health, Jabil, NeoGenomics, Darden, Cormedix Insider Moves
3M ago
GH
DRI
CorMedix price target lowered to $13 from $18 at H.C. Wainwright
PremiumThe FlyCorMedix price target lowered to $13 from $18 at H.C. Wainwright
3M ago
CRMD
CorMedix price target lowered to $13 from $22 at RBC Capital
Premium
The Fly
CorMedix price target lowered to $13 from $22 at RBC Capital
3M ago
CRMD
P/E Steals: 3 Overlooked Stocks Ready to Surge Over 100% in 2026
Premium
Market News
P/E Steals: 3 Overlooked Stocks Ready to Surge Over 100% in 2026
4M ago
DDI
BTBT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >